
Belma Pojskic

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10195782/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal, 2016, 37, 2999-3058.	2.2	2,393
2	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. New England Journal of Medicine, 2018, 379, 2097-2107.	27.0	2,211
3	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis, 2019, 290, 140-205.	0.8	1,753
4	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After AcuteÂCoronary Syndrome. Journal of the American College of Cardiology, 2020, 75, 133-144.	2.8	296
5	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 618-628.	11.4	207
6	Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. New England Journal of Medicine, 2018, 379, 1118-1127.	27.0	205
7	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis, 2018, 277, 234-255.	0.8	163
8	Alirocumab in Patients With Polyvascular Disease and Recent Acute CoronaryÂSyndrome. Journal of the American College of Cardiology, 2019, 74, 1167-1176.	2.8	154
9	Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events. Journal of the American College of Cardiology, 2019, 73, 387-396.	2.8	131
10	Effect of Alirocumab on Mortality After Acute Coronary Syndromes. Circulation, 2019, 140, 103-112.	1.6	107
11	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. Atherosclerosis Supplements, 2016, 22, 1-32.	1.2	90
12	Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. Journal of the American College of Cardiology, 2019, 74, 1177-1186.	2.8	49
13	Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. European Heart Journal, 2019, 40, 2801-2809.	2.2	45
14	Stroke prevention in atrial fibrillation and â€~real world' adherence to guidelines in the Balkan Region: The BALKAN-AF Survey. Scientific Reports, 2016, 6, 20432.	3.3	40
15	Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Circulation, 2019, 140, 1578-1589.	1.6	34
16	The Patterns of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Use in Patients with Atrial Fibrillation in Seven Balkan Countries: a Report from the BALKAN-AF Survey. Advances in Therapy, 2017, 34, 2043-2057.	2.9	17
17	Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005858.	2.2	17
18	The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project. Current Atherosclerosis Reports, 2019, 21, 36.	4.8	13

Belma Pojskic

#	Article	IF	CITATIONS
19	Acute Heart Failure After Myocardial Infarction. Bosnian Journal of Basic Medical Sciences, 2008, 7, 40-47.	1.0	3
20	Familial hypercholesterolemia screening program in Bosnia and Herzegovina and cardiovascular morbidity. Atherosclerosis, 2018, 277, 278-281.	0.8	2
21	Cardiac Sarcoidosis Mimicking Takotsubo Syndrome. Bosnian Journal of Basic Medical Sciences, 2008, 8, 234-238.	1.0	2
22	Influence of C-reactive protein on the occurrence and assessing of albuminuria severity in diabetics. Medicinski Glasnik, 2018, 15, 10-15.	0.4	2
23	Risk factor for NAFLD and CHD – similarity and differences. Atherosclerosis, 2017, 263, e259.	0.8	1
24	Therapeutic efficacy and toxicity of bolus application of chemotherapy protocol in the treatment of metastatic colorectal cancer. Medicinski Glasnik, 2015, 12, 206-11.	0.4	1
25	Comparison of intubation condition and the quality of muscle relaxation between rocuronium and vecuronium using "timing principle". Medicinski Glasnik, 2020, 17, 7-14.	0.4	1
26	Takayasu arteritis in bosnia- case report. Atherosclerosis, 2014, 235, e90.	0.8	0
27	Influence of lipids on mortality and morbidity in people aged over 80 in Bosnia. Atherosclerosis, 2015, 241, e116.	0.8	0
28	The lipid fractions as risk factors for atherosclerosis in different age groups in Bosnian population. Atherosclerosis, 2016, 252, e109.	0.8	0
29	Connection between foreign body in the eye and familial hypercholesterolemia –case report. Atherosclerosis, 2017, 263, e228.	0.8	0
30	Familial hypercholesterolemia in hospital screening program in Bosnia and Herzegovina. Atherosclerosis, 2018, 275, e178.	0.8	0
31	2 Statins Therapy In Acute Coronary Syndrome In Bosnia And Herzegovina. Atherosclerosis, 2019, 287, e193.	0.8	0
32	Familial chylomicronemia syndrome - Case report. Atherosclerosis, 2020, 315, e149-e150.	0.8	0
33	Lipid profile in young adults with acute myocardial infarction. Atherosclerosis, 2020, 315, e177.	0.8	0
34	Echocardiographic Monitoring of Patients with Heart Failure. Bosnian Journal of Basic Medical Sciences, 2008, 7, 339-344.	1.0	0
35	Evaluation of Risk Markers Fluctuation During an Initial Therapy with Rosiglitazon in Patients Suffering from Metabolic Syndrome. Bosnian Journal of Basic Medical Sciences, 2009, 9, 320-328.	1.0	0